Sumitomo Pharma Co., Ltd. (4506.T) JPX

1,440.00

+33(+2.35%)

Updated at August 22 03:30PM

Currency In JPY

Sumitomo Pharma Co., Ltd.

Address

6-8 Doshomachi 2-chome

Osaka, 541-0045

Japan

Phone

81 6 6203 5321

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

4980

First IPO Date

January 04, 2000

Key Executives

NameTitlePayYear Born
Mr. Toru Kimura Ph.D.Representative Director, President & Chief Executive Officer01960
Mr. Hideyuki HaradaMng. Exe. Off. of Supply Chain Div., SVice President, Hd. of Supply Chain Div. & Hd. of Japan Bus. Unit0N/A
Kimihiro MizunoExecutive Officer of Legal & Compliance; Intellectual Property & Human Resources0N/A
Mr. Isao ShimizuExecutive Off., SVice President and Dep. Head of Research and Development Div. of Drug Discovery Research0N/A
Mr. Yutaka WakemiExecutive Officer, Vice President & Head of Global Corporate Strategy0N/A
Mr. Koichi KozukiE.O. of Corporation Reg. Comp. & Q.A., Senior Vice President, Hd of C.R.C. & Q.A. Div and Dp. Hd of Japan Bus.0N/A
Dr. Shigeyuki Nishinaka Ph.D.Managing Executive Officer, Vice President and Head of Business Development & Management01964
Mr. Kenji UenoExecutive Officer, Senior Vice President and Deputy Head of Research and Development Division (CMC)0N/A
Dr. Tsutomu Nakagawa Ph.D.Managing Executive Officer & Director0N/A
Ms. Yumi SatoManaging Exe. Officer of Research & Dev. Div. Senior Vice President and Head of Research & Development Division0N/A

Description

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.